KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables - Net: 2009-2024

Historic Receivables - Net for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Dec 2024 value amounting to $98.7 million.

  • Acadia Pharmaceuticals' Receivables - Net rose 17.96% to $115.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.8 million, marking a year-over-year increase of 17.96%. This contributed to the annual value of $98.7 million for FY2024, which is 0.48% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Receivables - Net is $98.7 million, which was up 0.48% from $98.3 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Receivables - Net registered a high of $98.7 million during FY2024, and its lowest value of $48.2 million during FY2020.
  • Moreover, its 3-year median value for Receivables - Net was $98.3 million (2023), whereas its average is $86.4 million.
  • In the last 5 years, Acadia Pharmaceuticals' Receivables - Net decreased by 3.37% in 2022 and then skyrocketed by 58.00% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Receivables - Net (Yearly) stood at $48.2 million in 2020, then skyrocketed by 33.41% to $64.4 million in 2021, then decreased by 3.37% to $62.2 million in 2022, then spiked by 58.00% to $98.3 million in 2023, then increased by 0.48% to $98.7 million in 2024.